Evelo Biosciences Inc

NASDAQ:EVLO   3:59:50 PM EDT
4.99
-0.06 (-1.19%)
Products, Regulatory

Evelo Biosciences Inc - Co Announced Planned Updates To The Study Protocol For Its Phase 2 Clinical Trial Of EDP1815 In Atopic Dermatitis

Published: 12/22/2021 22:15 GMT
Evelo Biosciences Inc (EVLO) - Evelo Biosciences Inc - Co Announced Planned Updates to the Study Protocol for Its Phase 2 Clinical Trial of Edp1815 in Atopic Dermatitis.
Evelo Biosciences Inc - Decided to Increase Number of Participants in Phase 2 Clinical Trial of Edp1815 to 300, Extend the Dosing Period to 16 Weeks.
Evelo Biosciences-to Reduce Lowest Dose to Be Investigated in Phase 2 Atopic Dermatitis Trial.
Evelo Biosciences Inc - to Evaluate Edp1815 Drug Substance Produced Using 2 Different Making Processes in Phase 2 Trial.
Evelo Biosciences- Based on Planned Changes to Study Protocol, Dosing for Phase 2 Atopic Dermatitis Trial Expected to Begin in Q1 of 2022.
Evelo Biosciences Inc - Results From Phase 2 Atopic Dermatitis Trial Anticipated in the First Half of 2023.